ImmunoGen, CytomX swap licenses to develop anti-cancer Probody-drug conjugates
In a multi-year deal, next-generation antibody developer CytomX Therapeutics Inc. and ImmunoGen Inc. (antibody-drug conjugates; ADCs) agreed to develop anti-cancer Probody-drug conjugates (PDCs) against a certain number of targets. (NOTE: the lab code of one candidate is CD166, and another is CX2009).
- Controlled Release
- Site Specific
- Drug Delivery
- Drug Discovery Technologies
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.